BET bromodomain inhibitor 1
BET bromodomain inhibitor 1 is an orally active, selective bromodomain and extra-terminal (BET) bromodomain inhibitor with an IC50 of 2.6 nM for BRD4. BET bromodomain inhibitor 1 binds to BRD2 (2), BRD3 (2), BRD4 (1), BRD4 (2), and BRDT (2) with high affinities (Kd values of 1.3 nM, 1.0 nM, 3.0 nM, 1.6 nM, 2.1 nM, respectively) . bromodomain inhibitor 1 has anti-cancer activity[1].
Product Specifications
CAS Number
2411226-02-1
UNSPSC
12352005
Target
Epigenetic Reader Domain
Type
Reference compound
Related Pathways
Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/bet-bromodomain-inhibitor-1.html
Purity
99.91
Solubility
DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C1C2=C(C)C=C(C3=CC(CS(=O)(CC)=O)=CN=C3OC4=CC=C(F)C=C4F)N2C=CN1
Molecular Formula
C22H19F2N3O4S
Molecular Weight
459.47
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
BRD2; BRD3; BRD4; BRDT
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Cytokeratin 17 (E3), CF640R conjugate, 0.1mg/mL
Eosinophil Peroxidase (AHE-1), CF647 conjugate, 0.1mg/mL
CD63 (MX-49.129.5), CF488A conjugate, 0.1mg/mL
TAG-72 / CA72.4 (B72.3), CF640R conjugate, 0.1mg/mL
